Kailera Therapeutics

Eli Lilly and Company

Shares of biotech Kailera Therapeutics Inc. are available for trading on the Freedom client trading platform. The company’s lead asset, ribupatide, is part of the multibillion-dollar race for weight-loss drugs, a market expected to exceed $150 billion over the next decade. Later on Friday, the stock will start regular-session trading on the Nasdaq under the ticker symbol <a href="https://tap.freedom24.com/to/quote/HMH.US?utm_source=stocks&amp;utm_medium=HMH.US&amp;utm_campaign=pfu17521958">KLRA</a>.

Kailera Therapeutics IPO: Shares of obesity drugmaker start trading

Novo Nordisk A/S

Shares in manufacturer Ozempic jumped 3.5%

"Superpower Charge": Novo Nordisk bets on OpenAI in confrontation with Eli Lilly

Hims & Hers Health, Inc.

LifeMD, Inc.

“The enemy of my enemy is my friend,” points out Ilya Zubkov, Freedom Broker senior equity analyst, describing the situation that has unfolded this year between Danish pharmaceutical giant Novo Nordisk and telehealth platform and online pharmacy operator Hims &amp; Hers Health. The “enemies” are Novo Nordisk and its U.S. rival Eli Lilly, which have been competing for leadership in the obesity drug market for several years. Their rivalry has spilled over beyond the pharmaceutical sector, now affecting companies like Hims &amp; Hers Health. Overall, the weight-loss drug market is beginning to shift. Which small caps should investors watch?

The obesity therapy market is changing. What smid-cap investors should know.

Delta Air Lines, Inc.

American Airlines Group Inc.

All four major U.S. stock indexes rose for the second day in a row, with the Russell 2000 index of small and mid-capitalization companies rising the most. Stocks continued to rise in price, despite the fact that oil also increased in price. In the past days of the U.S. war with Iran, the stock market perceived it negatively and sold off stocks. Now investors are waiting for the Fed's rate decision and its comments on the situation.

Oil rose in price, but US stocks rose for the second straight day: results of the 18th day of the war

HSBC analysts called the market for obesity drugs "bloated"

Eli Lilly received a rare "sell" recommendation from analysts. Shares fell by 6%

Merck & Co., Inc.

Pharmaceutical stocks could be one of the defensive assets amid the escalating conflict in the Middle East, analysts at UBS said, their note <a href="https://www.cnbc.com/2026/03/06/market-turmoil-is-hitting-traditional-safe-havens-ubs-says-hide-here-.html">quoted by</a> CNBC.

'Most defensive sector': UBS names stocks that can 'safely survive war'

JPMorgan, Deutsche Bank and RBC Capital believe that pharmaceutical company Eli Lilly will be the main beneficiary of the rapidly growing market of GLP-1 weight loss drugs. Analysts point to the higher efficacy of its therapy compared to competitors, development of direct sales and potential expansion of insurance coverage.

Three investment banks named Eli Lilly as the leader in the weight loss drug race

A key objective of the trial was to confirm that Novo was as effective as a competitor's product, Eli Lilly

Novo's failure to test a weight loss drug has sparked a sell-off in the Danish market

Viking Therapeutics, Inc.

Risk-tolerant investors should not ignore shares of biotech Viking Therapeutics, Motley Fool analyst Adria Cimino <a href="https://www.fool.com/investing/2026/02/11/viking-therapeutics-the-undertheradar-glp1-contend/">argues</a>. This is because the company is developing an obesity drug that could compete with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound in the near term.

Motley Fool calls Viking the GLP‑1 drugmaker growth-hunting investors 'can't ignore'

Shares of Novo Nordisk and Eli Lilly, makers of popular weight-loss drugs, fell in price after Hims &amp; Hers, which owns a telemedicine platform,<a href="https://investors.hims.com/news/news-details/2026/Hims--Hers-Expands-Personalized-Weight-Loss-Portfolio-with-Access-to-Compounded-Semaglutide-Pills-Starting-at-49Month/default.aspx"> announced</a> the launch of its own copy of the Wegovy slimming pill. And it will cost just $49 - three times cheaper than Novo's original, which investors <a href="https://oninvest.com/article/novo-vpecatlil-investorov-zapustiv-v-ssa-tabletku-dla-pohudenia-cto-u-konkurentov">had </a>high hopes for.

Novo Nordisk and Eli Lilly shares plummet: the weight-loss pill will have a $49 copy

Alphabet Inc.

QUALCOMM Incorporated

Snap Inc.

Uber Technologies, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: statistics and corporate news will determine the trading vector

Novo a day earlier, by contrast, had warned of a decline in sales